Nobel prize goes to cancer treatment pioneers who saved ‘untold number of lives’

One cancer doctor said “an untold number of lives … have been saved by the science that they pioneered”.

James Allison of the University of Texas and Tasuku Honjo of Kyoto University will share the nine-million-kronor (£765,000) prize for 2018.

Their parallel work concerned proteins that act as brakes on the body’s immune system.

Their research, which has led to drugs that release the brakes on the immune system, constitutes “a landmark in our fight against cancer”, said the Nobel Assembly of Sweden’s Karolinska Institute, which selects the winners of the prestigious award.

The discoveries by Dr Allison, 70, and Mr Honjo, 76, “absolutely paved the way for a new approach to cancer treatment”, Dr Jedd Wolchok, chief of the melanoma and immunotherapeutics service at the Memorial Sloan Kettering Cancer Centre in New York, said.

He said the idea of releasing the brakes on immune system cells has led to drugs for the skin cancer melanoma and for cancers of the lung, head and neck, bladder, kidney and liver.

Just last week, such a drug was approved for treatment of another kind of skin cancer called squamous cell cancer, he said.

Dr Wolchok said “an untold number of lives … have been saved by the science that they pioneered”.

The approach to cancer treatment that was honoured with this year’s Nobel was used to treat former US president Jimmy Carter, who was diagnosed in 2015 with melanoma, which had spread to his brain.

One of Mr Carter’s treatments was a drug that blocked the immune-cell “brake” studied by Mr Honjo.

Mr Carter announced in 2016 that he no longer needed treatment.

Although the concept of using the immune system against cancer arose in the 19th century, initial treatments based on the approach were only modestly effective.

“Everybody wanted to do chemotherapy and radiation.

“The immune system was neglected because there was no strong evidence it could be effective,” said Nadia Guerra, head of a cancer laboratory at Imperial College London.

Dr Allison’s work, much of it done at the University of California-Berkeley, changed that by proving the immune system could identify tumour cells and act against them.

“It’s like your body uses your own army to fight cancer,” she said.

Dr Allison studied a known protein and developed the concept into a new treatment approach, while Honjo discovered a new protein that also operated as a brake on immune cells.

“I’m honoued and humbled to receive this prestigious recognition,” Dr Allison said in a statement released by the university’s M.D. Anderson Cancer Centre in Houston, where he is a professor.

“A driving motivation for scientists is simply to push the frontiers of knowledge. I didn’t set out to study cancer, but to understand the biology of T cells, these incredible cells that travel our bodies and work to protect us,” he said.

T cells are key immune system soldiers.

At news conference in Kyoto, Mr Honjo said what makes him most delighted is when he hears from patients who have recovered from serious illnesses because of his research.

Mr Honjo, an avid golf player, said a member of a golf club once walked up to him suddenly, thanking him for the discovery that treated his lung cancer.

“He told me, ‘Thanks to you I can play golf again.’ …That was a blissful moment. A comment like that makes me happier than any prize,” he said.

Dr Allison’s and Mr Honjo’s prize-winning work started in the 1990s and was part of significant advances in cancer immunotherapy.

Such treatment is also called “checkpoint therapy”, a term that inspired the name of the Checkpoints, a musical group of cancer researchers in which Dr Allison plays harmonica.

“In some patients, this therapy is remarkably effective,” Jeremy Berg, editor-in-chief of the Science family of journals, said.

“The number of different types of cancers for which this approach to immunotherapy is being found to be effective in at least some patients continues to grow.”

Therapy developed from Mr Honjo’s work led to long-term remission in patients with metastatic cancer that had been considered essentially untreatable, the Nobel Assembly said.

In other Nobel Prize announcements, the physics prize will be announced on Tuesday, followed by chemistry on Wednesday and the Nobel Peace Prize on Friday.

The economics laureate, which is not technically a Nobel but is given in honour of Alfred Nobel, the prizes’ founder, will be announced next Monday.

No Nobel Literature Prize is being given this year because the Swedish Academy, the body that choses the literature winner, has been in turmoil after sex abuse and financial scandal allegations.

The academy hopes to award both the 2018 prize and the 2019 literature prize next year.